Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Exclusion Criteria

• •Prior treatment with a taxane is not permitted in the dose-expansion phase. Patients in the dose escalation component may have received a taxane in the peri-operative setting, provided they developed disease recurrence \>6 months after the completion of this therapy
• •Known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)
• •Patients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollment
• •Uncontrolled hypertension (systolic pressure \>140 mm Hg or diastolic pressure \> 90 mm Hg on repeated measurement) despite optimal medical management
• •Active or clinically significant cardiac disease
• •Patients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollment